Blog
RSS FeedPosted by Michael Wonder on 25 Oct 2017
Institute for Clinical and Economic Review opens nominations for new members of its voting panels
26 October 2017 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other health ...
Posted by Michael Wonder on 12 Oct 2017
Institute for Clinical and Economic Review to evaluate cystic fibrosis treatments in upcoming report
12 October 2017 - Report expected to review tezacaftor, lumacaftor, and ivacaftor (Vertex Pharmaceuticals); Open Input accepted until 27 October. ...
Posted by Michael Wonder on 04 Oct 2017
Institute for Clinical and Economic Review Evidence Report finds cognitive and mind-body therapies for treatment of back pain provide added benefit at reasonable cost
4 October 2017 - More evidence needed to distinguish between therapies and to fully understand their effects in chronic neck pain. ...
Posted by Michael Wonder on 03 Oct 2017
Institute for Clinical and Economic Review releases draft evidence report on treatments for tardive dyskinesia
2 October 2017 - Public comment period now open until 30 October; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 30 Sep 2017
Institute for Clinical and Economic Review's final report confirms inadequate evidence to compare outcomes of PARP inhibitors for ovarian cancer, highlights poor cost-effectiveness, particularly for maintenance therapy
29 September 2017 - The ICER has issued a final evidence report assessing the comparative clinical effectiveness and value of ...
Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of emicizumab for haemophilia A
11 September 2017 - Document open to public comment until 29 September 2017. ...
Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favourable cost-effectiveness
11 September 2017 - To reflect new clinical trial evidence, updated ICER value-based price benchmark for a year of treatment ...
Posted by Michael Wonder on 09 Sep 2017
Should value frameworks take a ‘societal perspective’?
6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...
Posted by Michael Wonder on 09 Sep 2017
Can a new value framework help ease friction over orphan drug prices?
7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...
Posted by Michael Wonder on 31 Aug 2017
Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications
30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...
Posted by Michael Wonder on 15 Aug 2017
Institute for Clinical and Economic Review releases draft evidence report on cognitive and mind-body therapies for treatment of chronic low back and neck pain
15 August 2017 - Public comment period now open until 12 September; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 12 Aug 2017
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of emicizumab for haemophilia A
11 August 2017 - Open input period now open until 6 September 2017. ...
Posted by Michael Wonder on 09 Aug 2017
Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment
9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA. ...
Posted by Michael Wonder on 26 Jul 2017
Institute for Clinical and Economic Review announces potential topics for review in 2018
26 July 2017 - Tentative list includes drugs for migraines, haemophilia, and cystic fibrosis. ...
Posted by Michael Wonder on 25 Jul 2017
Dr Steve Pearson on using health technology assessment to guide decision making
23 July 2017 - Health technology assessment is a tool that helps to objectively evaluate evidence, which levels the playing field ...